Crystalvue Medical (6527) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 明達醫

Crystalvue Medical (6527) reported revenue of NT$98.7 million for Oct 2026, +12.3% year on year and +17.2% from the previous month. Revenue for Jan–Oct 2026 was NT$726.1 million (-5.7% year on year).

Revenue for Oct 2026 was a record high (previous high: Dec 2025, NT$98.4 million). →

In Oct 2026, it ranked No. 74 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$71.9 million24/10Nov 2024 NT$70.3 millionDec 2024 NT$81.6 millionJan 2025 NT$68.7 millionFeb 2025 NT$71.7 million25/02Mar 2025 NT$84.1 millionApr 2025 NT$81.7 millionMay 2025 NT$91.5 millionJun 2025 NT$83.2 million25/06Jul 2025 NT$58.4 millionAug 2025 NT$65.8 millionSep 2025 NT$76.7 millionOct 2025 NT$87.9 million25/10Nov 2025 NT$80.8 millionDec 2025 NT$98.4 millionJan 2026 NT$74.5 millionFeb 2026 NT$44.5 million26/02Mar 2026 NT$69.3 millionApr 2026 NT$61.6 millionMay 2026 NT$87.5 millionJun 2026 NT$68.7 million26/06Jul 2026 NT$73.1 millionAug 2026 NT$64 millionSep 2026 NT$84.3 millionOct 2026 NT$98.7 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$98.7 million+12.3%+17.2%
Sep 2026NT$84.3 million+9.8%+31.7%
Aug 2026NT$64 million-2.8%-12.5%
Jul 2026NT$73.1 million+25.2%+6.3%
Jun 2026NT$68.7 million-17.4%-21.4%
May 2026NT$87.5 million-4.4%+42.1%
Apr 2026NT$61.6 million-24.7%-11.2%
Mar 2026NT$69.3 million-17.6%+55.8%
Feb 2026NT$44.5 million-37.9%-40.3%
Jan 2026NT$74.5 million+8.5%-24.3%
Dec 2025NT$98.4 million+20.5%+21.7%
Nov 2025NT$80.8 million+14.9%-8.1%
Oct 2025NT$87.9 million+22.4%+14.6%
Sep 2025NT$76.7 million+9.7%+16.5%
Aug 2025NT$65.8 million-16.5%+12.8%
Jul 2025NT$58.4 million-30.8%-29.8%
Jun 2025NT$83.2 million+21.9%-9.1%
May 2025NT$91.5 million+30.9%+12.0%
Apr 2025NT$81.7 million+11.2%-2.8%
Mar 2025NT$84.1 million+27.6%+17.3%
Feb 2025NT$71.7 million+5.5%+4.4%
Jan 2025NT$68.7 million+4.4%-15.9%
Dec 2024NT$81.6 million+23.3%+16.1%
Nov 2024NT$70.3 million+14.5%-2.1%
Oct 2024NT$71.9 million+16.4%+2.8%

Jan–Oct 2026 cumulative: NT$726.1 million (-5.7% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Crystalvue Medical vs PEC / Crystalvue Medical vs Lotus Pharm / Crystalvue Medical vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16